arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Climb Bio, Inc.

CLYM

$14.01 ▲ +0.03 (+0.21%) at close

7 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Climb Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $950.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -33.4% ↘

FCF / Share $-0.80 ↘

Trailing P/E —

Price / Book 4.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-59.85M

↑ +19.0% —

FCF / Share Free cash flow per share

$-0.80

↓ -148.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	42.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-17.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	24.4% Good Good Year-over-year change in earnings per share Optimal: > 10%	59.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	19.0% Good ↑ Good Improving Year-over-year change in net income	-110.4% Weak ↓ Weak Declining Year-over-year change in net income	22.4% Good ↑ Good Improving Year-over-year change in net income	4.7% Caution Caution Year-over-year change in net income	-129.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-148.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	57.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	46.3% Excellent Excellent Year-over-year change in free cash flow	51.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.21x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-33.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-30.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	66.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-40.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-85.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-37.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-349%)	-34.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-333%)	-32.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-318%)	-35.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-334%)	-28.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-289%)	82.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+452%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-35.69M	$-87.23M	$-93.11M	$-43.59M	$-46.92M	$-20.49M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-0.88	$-1.53	$-1.30	$-1.72	$-4.24	—	—
Free Cash Flow per Share (USD)	$-0.80	$-0.32	$-0.76	$-1.42	$-2.94	—	—
Book Value per Share (USD)	$3.36	$3.15	$3.88	$4.84	$6.29	$-7.31	—
Tangible Book Value per Share (USD)	$3.36	$3.15	$3.88	$4.84	$6.29	$-7.31	—
Basic Weighted Avg Shares (shares)	67.81M	48.16M	26.99M	26.31M	12.26M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$98.86M	$149.94M	$107.42M	$128.30M	$142.22M	$18.93M	—
Total Equity (USD)	$160.47M	$211.88M	$107.60M	$128.72M	$167.20M	$-24.98M	$-5.56M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$97.00K	$0.00	—	—	—	—	—
Net Income, GAAP (USD)	$-59.85M	$-73.90M	$-35.12M	$-45.24M	$-47.48M	$-20.67M	—
Operating Cash Flow (USD)	$-54.36M	$-15.56M	$-20.60M	$-37.37M	$-36.07M	$-14.10M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Climb Bio, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CLYM with peers